Works by Takaguchi, Koichi

Results: 126
    1

    Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues.

    Published in:
    Clinical & Molecular Hepatology, 2025, v. 31, n. 3, p. 1003, doi. 10.3350/cmh.2024.1070
    By:
    • Rui Huang;
    • Dae Won Jun;
    • Hidenori Toyoda;
    • Yao-Chun Hsu;
    • Trinh, Huy;
    • Akito Nozaki;
    • Toru Ishikawa;
    • Tsunamasa Watanabe;
    • Haruki Uojima;
    • Huang, Daniel Q.;
    • Takashi Honda;
    • Yasuhito Tanaka;
    • Vutien, Philip;
    • Marciano, Sebastián;
    • Hiroshi Abe;
    • Masaru Enomoto;
    • Masanori Atsukawa;
    • Hirokazu Takahashi;
    • Kunihiko Tsuji;
    • Koichi Takaguchi
    Publication type:
    Article
    2

    Clinical Impact of Serum CRP Levels on Advanced HCC Treated With Durvalumab and Tremelimumab: A Multicentre Study.

    Published in:
    Liver International, 2025, v. 45, n. 7, p. 1, doi. 10.1111/liv.70192
    By:
    • Hatanaka, Takeshi;
    • Yata, Yutaka;
    • Hiraoka, Atsushi;
    • Tada, Toshifumi;
    • Hirooka, Masashi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Atsukawa, Masanori;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Kakizaki, Satoru;
    • Fukunishi, Shinya;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Tajiri, Kazuto;
    • Toyoda, Hidenori;
    • Koshiyama, Yuichi;
    • Ogawa, Chikara;
    • Nishikawa, Hiroki;
    • Nishimura, Takashi
    Publication type:
    Article
    3

    Factors Affecting an Increase in Spleen Volume and Association of Spleen Volume Variation with the Clinical Outcomes of Atezolizumab and Bevacizumab Treatment for Hepatocellular Carcinoma: A Retrospective Analysis.

    Published in:
    Oncology, 2025, v. 103, n. 2, p. 94, doi. 10.1159/000541002
    By:
    • Hatanaka, Takeshi;
    • Saito, Naoto;
    • Kakizaki, Satoru;
    • Hiraoka, Atsushi;
    • Tada, Toshifumi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Ishikawa, Toru;
    • Toyoda, Hidenori;
    • Kawata, Kazuhito;
    • Naganuma, Atsushi;
    • Yata, Yutaka;
    • Ohama, Hideko;
    • Matono, Tomomitsu;
    • Tada, Fujimasa;
    • Nouso, Kazuhiro;
    • Morishita, Asahiro;
    • Tsutsui, Akemi
    Publication type:
    Article
    4

    Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve Function.

    Published in:
    Oncology, 2023, v. 101, n. 10, p. 624, doi. 10.1159/000531316
    By:
    • Hiraoka, Atsushi;
    • Kumada, Takashi;
    • Tada, Toshifumi;
    • Hirooka, Masashi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Atsukawa, Masanori;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Fukunishi, Shinya;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Tajiri, Kazuto;
    • Ochi, Hironori;
    • Yasuda, Satoshi;
    • Toyoda, Hidenori;
    • Ogawa, Chikara;
    • Nishimura, Takashi;
    • Hatanaka, Takeshi;
    • Kakizaki, Satoru
    Publication type:
    Article
    5

    Comparison between Atezolizumab Plus Bevacizumab and Lenvatinib for Hepatocellular Carcinoma in Patients with Child-Pugh Class B in Real-World Clinical Settings.

    Published in:
    Oncology, 2023, v. 101, n. 9, p. 542, doi. 10.1159/000530028
    By:
    • Ohama, Hideko;
    • Hiraoka, Atsushi;
    • Tada, Toshifumi;
    • Hirooka, Masashi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Atsukawa, Masanori;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Fukunishi, Shinya;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Tajiri, Kazuto;
    • Ochi, Hironori;
    • Yasuda, Satoshi;
    • Toyoda, Hidenori;
    • Ogawa, Chikara;
    • Nishimura, Takashi;
    • Hatanaka, Takeshi;
    • Kakizaki, Satoru
    Publication type:
    Article
    6

    Nutritional Status Is Associated with Prognosis in Patients with Advanced Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab.

    Published in:
    Oncology, 2023, v. 101, n. 4, p. 270, doi. 10.1159/000527676
    By:
    • Tada, Toshifumi;
    • Kumada, Takashi;
    • Hiraoka, Atsushi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Hirooka, Masashi;
    • Takaguchi, Koichi;
    • Atsukawa, Masanori;
    • Fukunishi, Shinya;
    • Itobayashi, Ei;
    • Tsuji, Kunihiko;
    • Tajiri, Kazuto;
    • Ochi, Hironori;
    • Ishikawa, Toru;
    • Yasuda, Satoshi;
    • Ogawa, Chikara;
    • Toyoda, Hidenori;
    • Hatanaka, Takeshi;
    • Nishimura, Takashi;
    • Kakizaki, Satoru
    Publication type:
    Article
    7

    Clinical Predictor of Urinary Protein as Adverse Event Associated with Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma.

    Published in:
    Oncology, 2022, v. 100, n. 12, p. 645, doi. 10.1159/000526521
    By:
    • Hiraoka, Atsushi;
    • Kumada, Takashi;
    • Tada, Toshifumi;
    • Hirooka, Masashi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Atsukawa, Masanori;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Fukunishi, Shinya;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Tajiri, Kazuto;
    • Ochi, Hironori;
    • Yasuda, Satoshi;
    • Toyoda, Hidenori;
    • Ogawa, Chikara;
    • Nishimura, Takashi;
    • Hatanaka, Takeshi;
    • Kakizaki, Satoru
    Publication type:
    Article
    8

    Simple Scoring System for Predicting TACE Unsuitable among Intermediate-Stage Hepatocellular Carcinoma Patients in the Multiple Systemic Treatment Era.

    Published in:
    Oncology, 2022, v. 100, n. 2, p. 65, doi. 10.1159/000520292
    By:
    • Hiraoka, Atsushi;
    • Kumada, Takashi;
    • Kariyama, Kazuya;
    • Toyoda, Hidenori;
    • Yasuda, Satoshi;
    • Tsuji, Kunihiko;
    • Hatanaka, Takeshi;
    • Kakizaki, Satoru;
    • Naganuma, Atsushi;
    • Ishikawa, Toru;
    • Tada, Toshifumi;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Shimada, Noritomo;
    • Shibata, Hiroshi;
    • Tanaka, Takaaki;
    • Tsutsui, Akemi;
    • Nagano, Takuya;
    • Imai, Michitaka;
    • Nakamura, Shinichiro
    Publication type:
    Article
    9

    Impact of Early Lenvatinib Administration on Survival in Patients with Intermediate-Stage Hepatocellular Carcinoma: A Multicenter, Inverse Probability Weighting Analysis.

    Published in:
    Oncology, 2021, v. 99, n. 8, p. 518, doi. 10.1159/000515896
    By:
    • Tada, Toshifumi;
    • Kumada, Takashi;
    • Hiraoka, Atsushi;
    • Michitaka, Kojiro;
    • Atsukawa, Masanori;
    • Hirooka, Masashi;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Takaguchi, Koichi;
    • Kariyama, Kazuya;
    • Itobayashi, Ei;
    • Tajiri, Kazuto;
    • Shimada, Noritomo;
    • Shibata, Hiroshi;
    • Ochi, Hironori;
    • Yasuda, Satoshi;
    • Toyoda, Hidenori;
    • Fukunishi, Shinya;
    • Ohama, Hideko;
    • Kawata, Kazuhito
    Publication type:
    Article
    10

    Nutritional Index as Prognostic Indicator in Patients Receiving Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma.

    Published in:
    Oncology, 2020, v. 98, n. 5, p. 295, doi. 10.1159/000506293
    By:
    • Hiraoka, Atsushi;
    • Kumada, Takashi;
    • Tada, Toshifumi;
    • Fukunishi, Shinya;
    • Atsukawa, Masanori;
    • Hirooka, Masashi;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Takaguchi, Koichi;
    • Kariyama, Kazuya;
    • Itobayashi, Ei;
    • Tajiri, Kazuto;
    • Shimada, Noritomo;
    • Shibata, Hiroshi;
    • Ochi, Hironori;
    • Kawata, Kazuhito;
    • Toyoda, Hidenori;
    • Ohama, Hideko;
    • Tsutsui, Akemi;
    • Itokawa, Norio
    Publication type:
    Article
    11

    Early Relative Change in Hepatic Function with Lenvatinib for Unresectable Hepatocellular Carcinoma.

    Published in:
    Oncology, 2019, v. 97, n. 6, p. 334, doi. 10.1159/000502095
    By:
    • Hiraoka, Atsushi;
    • Kumada, Takashi;
    • Atsukawa, Masanori;
    • Hirooka, Masashi;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Takaguchi, Koichi;
    • Kariyama, Kazuya;
    • Itobayashi, Ei;
    • Tajiri, Kazuto;
    • Shimada, Noritomo;
    • Shibata, Hiroshi;
    • Ochi, Hironori;
    • Tada, Toshifumi;
    • Toyoda, Hidenori;
    • Nouso, Kazuhiro;
    • Tsutsui, Akemi;
    • Nagano, Takuya;
    • Itokawa, Norio;
    • Hayama, Korenobu
    Publication type:
    Article
    12

    Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma.

    Published in:
    Oncology, 2019, v. 97, n. 5, p. 277, doi. 10.1159/000501281
    By:
    • Hiraoka, Atsushi;
    • Kumada, Takashi;
    • Atsukawa, Masanori;
    • Hirooka, Masashi;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Takaguchi, Koichi;
    • Kariyama, Kazuya;
    • Itobayashi, Ei;
    • Tajiri, Kazuto;
    • Shimada, Noritomo;
    • Shibata, Hiroshi;
    • Ochi, Hironori;
    • Tada, Toshifumi;
    • Toyoda, Hidenori;
    • Nouso, Kazuhiro;
    • Tsutsui, Akemi;
    • Nagano, Takuya;
    • Itokawa, Norio;
    • Hayama, Korenobu
    Publication type:
    Article
    13

    Relationship of Atezolizumab plus Bevacizumab Treatment with Muscle Volume Loss in Unresectable Hepatocellular Carcinoma Patients: Multicenter Analysis.

    Published in:
    Liver Cancer (2235-1795), 2023, v. 12, n. 3, p. 209, doi. 10.1159/000527402
    By:
    • Hiraoka, Atsushi;
    • Kumada, Takashi;
    • Tada, Toshifumi;
    • Hirooka, Masashi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Atsukawa, Masanori;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Fukunishi, Shinya;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Tajiri, Kazuto;
    • Ochi, Hironori;
    • Yasuda, Satoshi;
    • Toyoda, Hidenori;
    • Ogawa, Chikara;
    • Nishimura, Takashi;
    • Hatanaka, Takeshi;
    • Kakizaki, Satoru
    Publication type:
    Article
    14

    What Can Be Done to Solve the Unmet Clinical Need of Hepatocellular Carcinoma Patients following Lenvatinib Failure?

    Published in:
    Liver Cancer (2235-1795), 2021, v. 10, n. 2, p. 115, doi. 10.1159/000513355
    By:
    • Atsushi Hiraoka;
    • Takashi Kumada;
    • Toshifumi Tada;
    • Kazuya Kariyama;
    • Joji Tani;
    • Shinya Fukunishi;
    • Masanori Atsukawa;
    • Masashi Hirooka;
    • Kunihiko Tsuji;
    • Toru Ishikawa;
    • Koichi Takaguchi;
    • Ei Itobayashi;
    • Kazuto Tajiri;
    • Noritomo Shimada;
    • Hiroshi Shibata;
    • Hironori Ochi;
    • Kazuhito Kawata;
    • Satoshi Yasuda;
    • Hidenori Toyoda;
    • Hideko Ohama
    Publication type:
    Article
    15

    EZ-ALBI Score for Predicting Hepatocellular Carcinoma Prognosis.

    Published in:
    Liver Cancer (2235-1795), 2020, v. 9, n. 6, p. 734, doi. 10.1159/000508971
    By:
    • Kariyama, Kazuya;
    • Nouso, Kazuhiro;
    • Hiraoka, Atsushi;
    • Wakuta, Akiko;
    • Oonishi, Ayano;
    • Kuzuya, Teiji;
    • Toyoda, Hidenori;
    • Tada, Toshifumi;
    • Tsuji, Kunihiko;
    • Itobayashi, Ei;
    • Ishikawa, Toru;
    • Takaguchi, Koichi;
    • Tsutsui, Akemi;
    • Shimada, Noritomo;
    • Kudo, Masatoshi;
    • Kumada, Takashi
    Publication type:
    Article
    16

    Post-Progression Treatment Eligibility of Unresectable Hepatocellular Carcinoma Patients Treated with Lenvatinib.

    Published in:
    Liver Cancer (2235-1795), 2020, v. 9, n. 1, p. 73, doi. 10.1159/000503031
    By:
    • Hiraoka, Atsushi;
    • Kumada, Takashi;
    • Fukunishi, Shinya;
    • Atsukawa, Masanori;
    • Hirooka, Masashi;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Takaguchi, Koichi;
    • Kariyama, Kazuya;
    • Itobayashi, Ei;
    • Tajiri, Kazuto;
    • Shimada, Noritomo;
    • Shibata, Hiroshi;
    • Ochi, Hironori;
    • Tada, Toshifumi;
    • Toyoda, Hidenori;
    • Yokohama, Keisuke;
    • Nouso, Kazuhiro;
    • Tsutsui, Akemi;
    • Nagano, Takuya
    Publication type:
    Article
    17

    Complications after Radiofrequency Ablation for Hepatocellular Carcinoma: A Multicenter Study Involving 9,411 Japanese Patients.

    Published in:
    Liver Cancer (2235-1795), 2020, v. 9, n. 1, p. 50, doi. 10.1159/000502744
    By:
    • Maeda, Masaki;
    • Saeki, Issei;
    • Sakaida, Isao;
    • Aikata, Hiroshi;
    • Araki, Yasuyuki;
    • Ogawa, Chikara;
    • Kariyama, Kazuya;
    • Nouso, Kazuhiro;
    • Kitamoto, Mikiya;
    • Kobashi, Haruhiko;
    • Sato, Shuichi;
    • Shibata, Hiroshi;
    • Joko, Kouji;
    • Takaki, Shintaro;
    • Takabatake, Hiroyuki;
    • Tsutsui, Akemi;
    • Takaguchi, Koichi;
    • Tomonari, Tetsu;
    • Nakamura, Shinichiro;
    • Nagahara, Takakazu
    Publication type:
    Article
    18
    19

    Predictive factors and survival outcome of conversion therapy for unresectable hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: Comparative analysis of conversion, partial response and complete response patients.

    Published in:
    Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 10, p. 1361, doi. 10.1111/apt.18237
    By:
    • Hatanaka, Takeshi;
    • Kakizaki, Satoru;
    • Hiraoka, Atsushi;
    • Tada, Toshifumi;
    • Hirooka, Masashi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Atsukawa, Masanori;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Fukunishi, Shinya;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Tajiri, Kazuto;
    • Toyoda, Hidenori;
    • Ogawa, Chikara;
    • Nishikawa, Hiroki;
    • Nishimura, Takashi;
    • Kawata, Kazuhito;
    • Kosaka, Hisashi
    Publication type:
    Article
    20

    Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real‐world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial.

    Published in:
    Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 2, p. 233, doi. 10.1111/apt.18037
    By:
    • Tada, Toshifumi;
    • Kumada, Takashi;
    • Hiraoka, Atsushi;
    • Hirooka, Masashi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Atsukawa, Masanori;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Fukunishi, Shinya;
    • Nishikawa, Hiroki;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Tajiri, Kazuto;
    • Koshiyama, Yuichi;
    • Toyoda, Hidenori;
    • Ogawa, Chikara;
    • Hatanaka, Takeshi;
    • Kakizaki, Satoru;
    • Kawata, Kazuhito
    Publication type:
    Article
    21

    Eltrombopag enables initiation and completion of pegylated interferon/ribavirin therapy in Japanese HCV-infected patients with chronic liver disease and thrombocytopenia.

    Published in:
    Experimental & Therapeutic Medicine, 2019, v. 18, n. 1, p. 596, doi. 10.3892/etm.2019.7616
    By:
    • Kawaguchi, Takumi;
    • Komori, Atsumasa;
    • Fujisaki, Kunio;
    • Nishiguchi, Shuhei;
    • Kato, Michio;
    • Takagi, Hitoshi;
    • Tanaka, Yasuhito;
    • Notsumata, Kazuo;
    • Mita, Eiji;
    • Nomura, Hideyuki;
    • Shibatoge, Mitsushige;
    • Takaguchi, Koichi;
    • Hattori, Toshihiro;
    • Sata, Michio;
    • Koike, Kazuhiko
    Publication type:
    Article
    22

    Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysis.

    Published in:
    Cancer Medicine, 2019, v. 8, n. 8, p. 3719, doi. 10.1002/cam4.2241
    By:
    • Hiraoka, Atsushi;
    • Kumada, Takashi;
    • Atsukawa, Masanori;
    • Hirooka, Masashi;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Takaguchi, Koichi;
    • Kariyama, Kazuya;
    • Itobayashi, Ei;
    • Tajiri, Kazuto;
    • Shimada, Noritomo;
    • Shibata, Hiroshi;
    • Ochi, Hironori;
    • Tada, Toshifumi;
    • Toyoda, Hidenori;
    • Nouso, Kazuhiro;
    • Tsutsui, Akemi;
    • Nagano, Takuya;
    • Itokawa, Norio;
    • Hayama, Korenobu
    Publication type:
    Article
    23

    Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions: Multicenter analysis.

    Published in:
    Cancer Medicine, 2019, v. 8, n. 1, p. 137, doi. 10.1002/cam4.1909
    By:
    • Hiraoka, Atsushi;
    • Kumada, Takashi;
    • Kariyama, Kazuya;
    • Takaguchi, Koichi;
    • Atsukawa, Masanori;
    • Itobayashi, Ei;
    • Tsuji, Kunihiko;
    • Tajiri, Kazuto;
    • Hirooka, Masashi;
    • Shimada, Noritomo;
    • Shibata, Hiroshi;
    • Ishikawa, Toru;
    • Ochi, Hironori;
    • Tada, Toshifumi;
    • Toyoda, Hidenori;
    • Nouso, Kazuhiro;
    • Tsutsui, Akemi;
    • Itokawa, Norio;
    • Imai, Michitaka;
    • Joko, Kouji
    Publication type:
    Article
    24

    Geriatric nutritional risk index and newly developed scoring system as prognosis prediction for unresectable hepatocellular carcinoma patients treated with lenvatinib.

    Published in:
    Scientific Reports, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41598-024-78539-4
    By:
    • Ohama, Hideko;
    • Hiraoka, Atsushi;
    • Tada, Toshifumi;
    • Hirooka, Masashi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Atsukawa, Masanori;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Fukunishi, Shinya;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Tajiri, Kazuto;
    • Ochi, Hironori;
    • Yasuda, Satoshi;
    • Toyoda, Hidenori;
    • Ogawa, Chikara;
    • Nishimura, Takashi;
    • Hatanaka, Takeshi;
    • Kakizaki, Satoru
    Publication type:
    Article
    25

    The efficacy and safety of glecaprevir plus pibrentasvir in 141 patients with severe renal impairment: a prospective, multicenter study.

    Published in:
    Alimentary Pharmacology & Therapeutics, 2019, v. 49, n. 9, p. 1230, doi. 10.1111/apt.15218
    By:
    • Atsukawa, Masanori;
    • Tsubota, Akihito;
    • Toyoda, Hidenori;
    • Takaguchi, Koichi;
    • Nakamuta, Makoto;
    • Watanabe, Tsunamasa;
    • Michitaka, Kojiro;
    • Ikegami, Tadashi;
    • Nozaki, Akito;
    • Uojima, Haruki;
    • Fukunishi, Shinya;
    • Genda, Takuya;
    • Abe, Hiroshi;
    • Hotta, Naoki;
    • Tsuji, Kunihiko;
    • Ogawa, Chikara;
    • Tachi, Yoshihiko;
    • Shima, Toshihide;
    • Shimada, Noritomo;
    • Kondo, Chisa
    Publication type:
    Article
    26

    Identification of CT Values That Could Be Predictive of Necrosis (N-CTav) in Hepatocellular Carcinoma after Lenvatinib Treatment.

    Published in:
    Current Oncology, 2022, v. 29, n. 5, p. 3259, doi. 10.3390/curroncol29050266
    By:
    • Chuma, Makoto;
    • Yokoo, Hideki;
    • Hiraoka, Atsushi;
    • Ueda, Kazuhiko;
    • Yokoyama, Takahiro;
    • Tsuji, Kunihiko;
    • Shimada, Noritomo;
    • Uojima, Haruki;
    • Kobayashi, Satoshi;
    • Hattori, Nobuhiro;
    • Okubo, Tomomi;
    • Atsukawa, Masanori;
    • Ishikawa, Toru;
    • Takaguchi, Koichi;
    • Tsutsui, Akemi;
    • Toyoda, Hidenori;
    • Tada, Toshifumi;
    • Saito, Yoshinori;
    • Hirose, Shunji;
    • Tanaka, Takaaki
    Publication type:
    Article
    27

    Characteristics and Prognosis of Hepatocellular Carcinoma in Japanese Patients Undergoing Dialysis.

    Published in:
    Therapeutic Apheresis & Dialysis, 2017, v. 21, n. 5, p. 465, doi. 10.1111/1744-9987.12563
    By:
    • Toyoda, Hidenori;
    • Hiraoka, Atsushi;
    • Tada, Toshifumi;
    • Michitaka, Kojiro;
    • Takaguchi, Koichi;
    • Tsuji, Kunihiko;
    • Itobayashi, Ei;
    • Takizawa, Daichi;
    • Hirooka, Masashi;
    • Koizumi, Yohei;
    • Ochi, Hironori;
    • Joko, Koji;
    • Kisaka, Yoshiyasu;
    • Shimizu, Yuko;
    • Tajiri, Kazuto;
    • Tani, Joji;
    • Taniguchi, Tatsuya;
    • Toshimori, Akiko;
    • Fujioka, Shinichi;
    • Kumada, Takashi
    Publication type:
    Article
    28

    Sequential therapy from entecavir to tenofovir alafenamide versus continuous entecavir monotherapy for patients with chronic hepatitis B.

    Published in:
    JGH Open, 2021, v. 5, n. 1, p. 34, doi. 10.1002/jgh3.12443
    By:
    • Itokawa, Norio;
    • Atsukawa, Masanori;
    • Tsubota, Akihito;
    • Takaguchi, Koichi;
    • Nakamuta, Makoto;
    • Hiraoka, Atsushi;
    • Kato, Keizo;
    • Abe, Hiroshi;
    • Mikami, Shigeru;
    • Shimada, Noritomo;
    • Chuma, Makoto;
    • Akito, Nozaki;
    • Uojima, Haruki;
    • Ogawa, Chikara;
    • Asano, Toru;
    • Tani, Joji;
    • Morishita, Asahiro;
    • Senoh, Tomonori;
    • Yamashita, Naoki;
    • Oikawa, Tsunekazu
    Publication type:
    Article
    29
    30
    31

    Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinoma.

    Published in:
    Gastroenterology Report, 2021, v. 9, n. 2, p. 133, doi. 10.1093/gastro/goaa042
    By:
    • Hiraoka, Atsushi;
    • Kumada, Takashi;
    • Tada, Toshifumi;
    • Ogawa, Chikara;
    • Tani, Joji;
    • Fukunishi, Shinya;
    • Atsukawa, Masanori;
    • Hirooka, Masashi;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Takaguchi, Koichi;
    • Kariyama, Kazuya;
    • Itobayashi, Ei;
    • Tajiri, Kazuto;
    • Shimada, Noritomo;
    • Shibata, Hiroshi;
    • Ochi, Hironori;
    • Kawata, Kazuhito;
    • Toyoda, Hidenori;
    • Ohama, Hideko
    Publication type:
    Article
    32

    Survival Outcomes Associated With Radiological Progressive Disease Subtypes in Patients With Atezolizumab and Bevacizumab–Treated HCC.

    Published in:
    Journal of Gastroenterology & Hepatology, 2025, v. 40, n. 4, p. 949, doi. 10.1111/jgh.16884
    By:
    • Matono, Tomomitsu;
    • Tada, Toshifumi;
    • Kumada, Takashi;
    • Hiraoka, Atsushi;
    • Hirooka, Masashi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Atsukawa, Masanori;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Fukunishi, Shinya;
    • Nishikawa, Hiroki;
    • Tanaka, Kazunari;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Tajiri, Kazuto;
    • Koshiyama, Yuichi;
    • Toyoda, Hidenori;
    • Ogawa, Chikara;
    • Hatanaka, Takeshi
    Publication type:
    Article
    33

    Reliable Performance of mALBI Grade‐Based Risk Models for Predicting the Prognosis of Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab as First‐Line Treatment: Comparative Analysis of 13 Risk Models.

    Published in:
    Journal of Gastroenterology & Hepatology, 2025, v. 40, n. 4, p. 930, doi. 10.1111/jgh.16871
    By:
    • Hatanaka, Takeshi;
    • Kakizaki, Satoru;
    • Hiraoka, Atsushi;
    • Tada, Toshifumi;
    • Hirooka, Masashi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Atsukawa, Masanori;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Fukunishi, Shinya;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Tajiri, Kazuto;
    • Toyoda, Hidenori;
    • Ogawa, Chikara;
    • Nishikawa, Hiroki;
    • Nishimura, Takashi;
    • Kawata, Kazuhito;
    • Kosaka, Hisashi
    Publication type:
    Article
    34

    Comparison of six hepatocellular carcinoma prediction models in Japanese patients after sustained virologic response undergoing rigorous surveillance for hepatocellular carcinoma.

    Published in:
    Journal of Gastroenterology & Hepatology, 2024, v. 39, n. 5, p. 949, doi. 10.1111/jgh.16494
    By:
    • Toyoda, Hidenori;
    • Tada, Toshifumi;
    • Uojima, Haruki;
    • Nozaki, Akito;
    • Chuma, Makoto;
    • Takaguchi, Koichi;
    • Hiraoka, Atsushi;
    • Abe, Hiroshi;
    • Itobayashi, Ei;
    • Matsuura, Kentaro;
    • Atsukawa, Masanori;
    • Watanabe, Tsunamasa;
    • Shimada, Noritomo;
    • Nakamuta, Makoto;
    • Kojima, Motoyuki;
    • Tsuji, Kunihiko;
    • Mikami, Shigeru;
    • Ishikawa, Toru;
    • Yasuda, Satoshi;
    • Tsutsui, Akemi
    Publication type:
    Article
    35

    Impact of first‐line systemic therapy with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.

    Published in:
    Journal of Gastroenterology & Hepatology, 2023, v. 38, n. 8, p. 1389, doi. 10.1111/jgh.16225
    By:
    • Tada, Toshifumi;
    • Kumada, Takashi;
    • Hiraoka, Atsushi;
    • Hirooka, Masashi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Atsukawa, Masanori;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Fukunishi, Shinya;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Tajiri, Kazuto;
    • Ochi, Hironori;
    • Yasuda, Satoshi;
    • Toyoda, Hidenori;
    • Ogawa, Chikara;
    • Nishimura, Takashi;
    • Hatanaka, Takeshi;
    • Kakizaki, Satoru
    Publication type:
    Article
    36

    Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting.

    Published in:
    Journal of Gastroenterology & Hepatology, 2021, v. 36, n. 7, p. 1812, doi. 10.1111/jgh.15336
    By:
    • Hiraoka, Atsushi;
    • Kumada, Takashi;
    • Kariyama, Kazuya;
    • Tada, Toshifumi;
    • Tani, Joji;
    • Fukunishi, Shinya;
    • Atsukawa, Masanori;
    • Hirooka, Masashi;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Tajiri, Kazuto;
    • Shimada, Noritomo;
    • Shibata, Hiroshi;
    • Ochi, Hironori;
    • Kawata, Kazuhito;
    • Yasuda, Satoshi;
    • Toyoda, Hidenori;
    • Ohama, Hideko
    Publication type:
    Article
    37

    Marked heterogeneity in the diagnosis of compensated cirrhosis of patients with chronic hepatitis C virus infection in a real‐world setting: A large, multicenter study from Japan.

    Published in:
    Journal of Gastroenterology & Hepatology, 2020, v. 35, n. 8, p. 1420, doi. 10.1111/jgh.14982
    By:
    • Toyoda, Hidenori;
    • Atsukawa, Masanori;
    • Watanabe, Tsunamasa;
    • Nakamuta, Makoto;
    • Uojima, Haruki;
    • Nozaki, Akito;
    • Takaguchi, Koichi;
    • Fujioka, Shinichi;
    • Iio, Etsuko;
    • Shima, Toshihide;
    • Akahane, Takehiro;
    • Fukunishi, Shinya;
    • Asano, Toru;
    • Michitaka, Kojiro;
    • Tsuji, Kunihiko;
    • Abe, Hiroshi;
    • Mikami, Shigeru;
    • Okubo, Hironao;
    • Okubo, Tomomi;
    • Shimada, Noritomo
    Publication type:
    Article
    38

    Analysis of factors associated with the prognosis of cirrhotic patients who were treated with tolvaptan for hepatic edema.

    Published in:
    Journal of Gastroenterology & Hepatology, 2020, v. 35, n. 7, p. 1229, doi. 10.1111/jgh.14965
    By:
    • Atsukawa, Masanori;
    • Tsubota, Akihito;
    • Takaguchi, Koichi;
    • Toyoda, Hidenori;
    • Iwasa, Motoh;
    • Ikegami, Tadashi;
    • Chuma, Makoto;
    • Nozaki, Akito;
    • Uojima, Haruki;
    • Hiraoka, Atsushi;
    • Fukunishi, Shinya;
    • Yokohama, Keisuke;
    • Tada, Toshifumi;
    • Kato, Keizo;
    • Abe, Hiroshi;
    • Tani, Joji;
    • Okubo, Hironao;
    • Watanabe, Tsunamasa;
    • Hattori, Nobuhiro;
    • Tsutsui, Akemi
    Publication type:
    Article
    39

    Real‐world experience of 12‐week direct‐acting antiviral regimen of glecaprevir and pibrentasvir in patients with chronic hepatitis C virus infection.

    Published in:
    Journal of Gastroenterology & Hepatology, 2020, v. 35, n. 5, p. 855, doi. 10.1111/jgh.14874
    By:
    • Toyoda, Hidenori;
    • Atsukawa, Masanori;
    • Watanabe, Tsunamasa;
    • Nakamuta, Makoto;
    • Uojima, Haruki;
    • Nozaki, Akito;
    • Takaguchi, Koichi;
    • Fujioka, Shinichi;
    • Iio, Etsuko;
    • Shima, Toshihide;
    • Akahane, Takehiro;
    • Fukunishi, Shinya;
    • Asano, Toru;
    • Michitaka, Kojiro;
    • Tsuji, Kunihiko;
    • Abe, Hiroshi;
    • Mikami, Shigeru;
    • Okubo, Hironao;
    • Okubo, Tomomi;
    • Shimada, Noritomo
    Publication type:
    Article
    40

    Monitoring serum proangiogenic cytokines from hepatocellular carcinoma patients treated with sorafenib.

    Published in:
    Journal of Gastroenterology & Hepatology, 2019, v. 34, n. 6, p. 1081, doi. 10.1111/jgh.14535
    By:
    • Adachi, Takuya;
    • Nouso, Kazuhiro;
    • Miyahara, Koji;
    • Oyama, Atsushi;
    • Wada, Nozomu;
    • Dohi, Chihiro;
    • Takeuchi, Yasuto;
    • Yasunaka, Tetsuya;
    • Onishi, Hideki;
    • Ikeda, Fusao;
    • Nakamura, Shinichiro;
    • Shiraha, Hidenori;
    • Takaki, Akinobu;
    • Takabatake, Hiroyuki;
    • Fujioka, Shin‐ichi;
    • Kobashi, Haruhiko;
    • Takuma, Yoshitaka;
    • Iwadou, Shouta;
    • Uematsu, Shuji;
    • Takaguchi, Koichi
    Publication type:
    Article
    41

    Efficacy and safety of elbasvir/grazoprevir for Japanese patients with genotype 1b chronic hepatitis C complicated by chronic kidney disease, including those undergoing hemodialysis: A post hoc analysis of a multicenter study.

    Published in:
    Journal of Gastroenterology & Hepatology, 2019, v. 34, n. 2, p. 364, doi. 10.1111/jgh.14447
    By:
    • Atsukawa, Masanori;
    • Kondo, Chisa;
    • Iwakiri, Katsuhiko;
    • Asano, Toru;
    • Ishikawa, Toru;
    • Abe, Hiroshi;
    • Kato, Keizo;
    • Tsuji, Kunihiko;
    • Ogawa, Chikara;
    • Shimada, Noritomo;
    • Iio, Etsuko;
    • Tanaka, Yasuhito;
    • Mikami, Shigeru;
    • Tsubota, Akihito;
    • Matsumoto, Yoshihiro;
    • Toyoda, Hidenori;
    • Kumada, Takashi;
    • Takaguchi, Koichi;
    • Okubo, Tomomi;
    • Hiraoka, Atsushi
    Publication type:
    Article
    42
    43

    Baseline factors and very early viral response (week 1) for predicting sustained virological response in telaprevir-based triple combination therapy for Japanese genotype 1b chronic hepatitis C patients: a multicenter study.

    Published in:
    Journal of Gastroenterology, 2014, v. 49, n. 11, p. 1485, doi. 10.1007/s00535-013-0918-7
    By:
    • Shimada, Noritomo;
    • Toyoda, Hidenori;
    • Tsubota, Akihito;
    • Ide, Tatsuya;
    • Takaguchi, Koichi;
    • Kato, Keizo;
    • Kondoh, Masaki;
    • Matsuyama, Kazuhiro;
    • Kumada, Takashi;
    • Sata, Michio
    Publication type:
    Article
    44
    45

    Real-World Virological Efficacy and Safety of Ledipasvir and Sofosbuvir in Patients with Chronic Hepatitis C Virus Genotype 2 Infection: A Multicenter Study.

    Published in:
    Infectious Diseases & Therapy, 2021, v. 10, n. 1, p. 269, doi. 10.1007/s40121-020-00364-9
    By:
    • Tada, Toshifumi;
    • Kumada, Takashi;
    • Okushin, Hiroaki;
    • Tani, Joji;
    • Takaguchi, Koichi;
    • Tsutsui, Akemi;
    • Toyoda, Hidenori;
    • Yasuda, Satoshi;
    • Dohmen, Kazufumi;
    • Hiraoka, Atsushi;
    • Michitaka, Kojiro;
    • Nouso, Kazuhiro;
    • Kariyama, Kazuya;
    • Kim, Soo Ryang;
    • Kim, Soo Ki;
    • Fujioka, Shinichi;
    • Mikami, Shigeru;
    • Watanabe, Yuto;
    • Tamai, Tsutomu;
    • Atsukawa, Masanori
    Publication type:
    Article
    46

    Real-World Clinical Application of 12-Week Sofosbuvir/Velpatasvir Treatment for Decompensated Cirrhotic Patients with Genotype 1 and 2: A Prospective, Multicenter Study.

    Published in:
    Infectious Diseases & Therapy, 2020, v. 9, n. 4, p. 851, doi. 10.1007/s40121-020-00329-y
    By:
    • Atsukawa, Masanori;
    • Tsubota, Akihito;
    • Kondo, Chisa;
    • Toyoda, Hidenori;
    • Nakamuta, Makoto;
    • Takaguchi, Koichi;
    • Watanabe, Tsunamasa;
    • Hiraoka, Atsushi;
    • Uojima, Haruki;
    • Ishikawa, Toru;
    • Iwasa, Motoh;
    • Tada, Toshifumi;
    • Nozaki, Akito;
    • Chuma, Makoto;
    • Fukunishi, Shinya;
    • Asai, Akira;
    • Asano, Toru;
    • Ogawa, Chikara;
    • Abe, Hiroshi;
    • Hotta, Naoki
    Publication type:
    Article
    47

    International multicenter validation of GES score for HCC risk stratification in chronic hepatitis C patients.

    Published in:
    Journal of Viral Hepatitis, 2022, v. 29, n. 9, p. 807, doi. 10.1111/jvh.13717
    By:
    • Shiha, Gamal;
    • Soliman, Reham;
    • Mikhail, Nabiel N. H.;
    • Carrat, Fabrice;
    • Azzi, Jessica;
    • Nathalie, Ganne‐Carrié;
    • Toyoda, Hidenori;
    • Uojima, Haruki;
    • Nozaki, Akito;
    • Takaguchi, Koichi;
    • Hiraoka, Atsushi;
    • Atsukawa, Masanori;
    • Abe, Hiroshi;
    • Matsuura, Kentaro;
    • Mikami, Shigeru;
    • Watanabe, Tsunamasa;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Suri, Vithika;
    • Osinusi, Anu
    Publication type:
    Article
    48

    Evaluation of 8‐week glecaprevir/pibrentasvir treatment in direct‐acting antiviral‐naïve noncirrhotic HCV genotype 1 and 2infected patients in a real‐world setting in Japan.

    Published in:
    Journal of Viral Hepatitis, 2019, v. 26, n. 11, p. 1266, doi. 10.1111/jvh.13170
    By:
    • Ikeda, Hiroki;
    • Watanabe, Tsunamasa;
    • Atsukawa, Masanori;
    • Toyoda, Hidenori;
    • Takaguchi, Koichi;
    • Nakamuta, Makoto;
    • Matsumoto, Nobuyuki;
    • Okuse, Chiaki;
    • Tada, Toshifumi;
    • Tsutsui, Akemi;
    • Yamashita, Naoki;
    • Kondo, Chisa;
    • Hayama, Korenobu;
    • Kato, Keizo;
    • Itokawa, Norio;
    • Arai, Taeang;
    • Shimada, Noritomo;
    • Asano, Toru;
    • Uojima, Haruki;
    • Ogawa, Chikara
    Publication type:
    Article
    49
    50

    Evaluation of Treatment Outcomes Using dNLR and GNRI in Combination Therapy With Atezolizumab and Bevacizumab for Hepatocellular Carcinoma.

    Published in:
    Cancer Medicine, 2025, v. 14, n. 2, p. 1, doi. 10.1002/cam4.70618
    By:
    • Naganuma, Atsushi;
    • Kakizaki, Satoru;
    • Hiraoka, Atsushi;
    • Tada, Toshifumi;
    • Hatanaka, Takeshi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Atsukawa, Masanori;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Fukunishi, Shinya;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Tajiri, Kazuto;
    • Toyoda, Hidenori;
    • Ogawa, Chikara;
    • Nishikawa, Hiroki;
    • Nishimura, Takashi;
    • Kawata, Kazuhito;
    • Kosaka, Hisashi
    Publication type:
    Article